Please login to the form below

Not currently logged in
Email:
Password:

U3 Pharma

This page shows the latest U3 Pharma news and features for those working in and with pharma, biotech and healthcare.

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer

The two-stage trial of patritumab (U3-1287/AMG 888) in combination with Roche's EGFR inhibitor Tarceva (erlotinib) patients with non-small cell lung cancer (NSCLC) was stopped on the ... The antibody was developed by Daiichi Sankyo's German subsidiary U3

Latest news

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    Will transfer its operations to a research unit in Japan.  . Daiichi Sankyo has said it will close down its German antibody subsidiary U3 Pharma and transfer its operations to a research ... Martinsried-based U3 Pharma - which was acquired by Daiichi

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics